reSee.it - Related Video Feed

Ozempic, a medication containing semaglutide, is gaining attention for its weight loss effects, but it has been linked to a side effect termed "Ozempic face," where users appear gaunt and unhealthy. Celebrities like Oprah and Scott Disick have openly discussed their experiences with rapid weight loss and its impact on their appearance. Ozempic works by activating GLP-1 receptors, signaling the brain to reduce appetite, leading to significant weight loss—averaging 15-20% of body weight. However, this rapid weight loss can result in muscle loss, nutrient deficiencies, and changes in skin appearance due to decreased protein and fat intake. The hosts emphasize the importance of maintaining a high protein diet, hydration, and strength training to mitigate these effects. They recommend supplements like protein powder, essential fatty acids, multivitamins, and electrolytes to support health during calorie restriction. Overall, the conversation highlights the complexities of weight loss and the potential consequences of using GLP-1 medications without proper nutritional support.

GLP-1s, like semaglutide (Ozempic), target specific genes related to muscle retention and bone density, offering more than just weight loss benefits. Dr. William Seeds emphasizes that these peptides can change cellular phenotypes, improving insulin sensitivity and glucose absorption. Initially developed for type 2 diabetes, GLP-1s also show potential in addressing neurodegenerative diseases by reducing inflammation in the brain. Patients often experience reduced cravings and improved decision-making regarding food, leading to healthier habits. However, effective use requires a comprehensive approach, including diet and exercise, as muscle loss can occur without proper resistance training. Dr. Seeds warns against self-administering unregulated peptides from online sources, as they may contain harmful substances. He advocates for working with experienced physicians to navigate potential side effects and implement lifestyle changes. The goal is to empower individuals to take control of their health, fostering a positive cycle of well-being and encouraging others to do the same.

In this episode, Steven Bartlett speaks with Johann Hari, bestselling author, about the transformative effects and risks associated with the weight loss drug Ozempic. Johann shares his personal journey of losing three stone and the profound impact Ozempic had on his appetite, reducing his hunger by 80%. He discusses the cultural shift towards using drugs for weight loss after decades of promoting diet and exercise, noting that only 10% of people maintain significant weight loss through traditional methods. Johann highlights the extraordinary benefits of Ozempic, including its ability to reverse obesity and reduce health risks associated with being overweight. He mentions that the average user can lose 15% of their body weight in a year, with newer drugs potentially offering even greater results. However, he expresses concern over the 12 significant risks associated with these drugs, including muscle mass loss, potential suicidal feelings, and the grim reality that 70% of weight lost is often regained within a year of stopping the medication. The conversation touches on the societal implications of widespread drug use for weight loss, with Johann reflecting on his experiences at a party where he noticed many attendees had lost weight, attributing it to Ozempic. He recounts a moment of realization when a friend introduced him to the drug, leading him to explore its effects and the conflicting emotions surrounding its use. Johann emphasizes the need for a nuanced understanding of the drug's impact on mental health, particularly regarding eating disorders. He shares alarming statistics about the rise of eating disorders during the pandemic and warns that the accessibility of Ozempic could exacerbate these issues, especially among young people. The discussion also delves into the science behind Ozempic, explaining how it mimics the hormone GLP-1, which signals fullness. Johann notes that while the drug can help reduce cravings for unhealthy foods, it may also dampen the reward system in the brain, leading to concerns about its long-term psychological effects. As the conversation progresses, Johann reflects on the broader context of obesity and the food industry, arguing that the rise in obesity is linked to changes in food supply and societal pressures. He advocates for a comprehensive approach to addressing obesity, including regulatory measures similar to those used in Japan, where public health initiatives have successfully reduced obesity rates. Johann shares anecdotes from his research, including a compelling experiment with rats that demonstrated how exposure to unhealthy foods can alter their eating behavior. He discusses the importance of understanding the psychological factors that drive eating habits and the need for societal change to combat the obesity crisis. The episode concludes with Johann expressing hope that the conversation around Ozempic and weight loss drugs will lead to greater awareness of the underlying issues contributing to obesity. He emphasizes the importance of addressing the food environment and promoting healthier choices, while also acknowledging the complex relationship individuals have with food and body image.

Obesity in America isn’t just a mystery; it’s explained as an environmental and biological match. After the 1950s, the price, palatability, accessibility, and convenience of food rose exponentially. Food became cheap, abundant, and quick to obtain, whether at a Buc-ee’s, a fast-food drive-thru, or a grocery run. People love highly tasty, calorie-dense foods, and calorie density is easier to achieve than ever. The main driver isn’t simple willpower but a combination of genetic hunger signaling and the modern food landscape. In short, population-wide obesity patterns emerge where abundant, tasty food meets varied hunger drives. Against this backdrop, new medications such as Ozempic and tirzepatide have changed the obesity equation by lowering hunger and food drive. They work primarily by reducing appetite, making dieting easier than ever before; for many people they enable meaningful weight loss or weight maintenance. The guest notes additional benefits like glucose clearance and potential cognitive effects, but also warns about side effects and the risk of gastroparesis at high doses. Drugs can be empowering tools or crutches, depending on how people use them. He points to ongoing drug development, including fifth and beyond generation therapies, and to the idea that some individuals won’t tolerate these meds. Conversations shift to the economics of food: corporations respond to ROI, not morality. The claim that 'they want you fat' is rejected; instead, the market rewards what people buy. Healthy options will appear if they are profitable; otherwise they stay sidelined. The guest cites the Minnesota semi-starvation study to illustrate how calorie restriction can intensify food obsession, and argues that long-run health outcomes depend on incentives rather than rhetoric. Personal responsibility matters, but genetics and environment set the stage; sustained changes come from consistent habits and long-term strategies, not quick fixes. On fitness practice, the host and guest advocate practical, scalable routines: two 20–30 minute sessions weekly for beginners, focusing on compound movements with short rests, escalating to more sessions as needed. They discuss gauging intensity by approaching near-failure and noticing increasing effort as reps accumulate. They also explore future pharmacology, including potential anabolic drugs and myostatin inhibitors, and the promise of AI-assisted drug discovery to accelerate development. Renaissance Periodization is framed as a science-based shift from vibes to data-driven training, with a long-term mission to help people get in better shape. Toward the end they touch on mental health and youth, noting a perceived rise in anxiety among young men, while cautioning that data and media narratives can be misleading. They suggest channeling energy into meaningful work, regular training, and social connection to reduce stress. They emphasize that corporate incentives and regulatory environments shape health outcomes, and that progress will come from aligning incentives so products genuinely improve long-term well-being. The conversation ends with cautious optimism that technology and thoughtful entrepreneurship can deliver better health through science and better systems.

GLP-1 medications like Ozempic and Mounjaro are effective for weight loss but can lead to muscle loss, with studies showing up to 40% of weight lost may come from lean body mass. This occurs because a significant calorie deficit prompts the body to reduce energy demands, including muscle mass. To mitigate muscle loss while on GLP-1s, it's crucial to adjust dosage, maintain a high-protein diet (around 1 gram per pound of target body weight), and engage in daily weight lifting, even if briefly. Staying hydrated is essential, as GLP-1s can dampen thirst signals. Supplements like essential amino acids, creatine, and electrolytes can also help preserve muscle. Proper use of GLP-1s can lead to effective fat loss while minimizing muscle loss.

In this episode, hosts Saam Paar and Shaan Puri discuss the drug semaglutide, originally developed for diabetes, which has gained popularity for weight loss among celebrities and the wealthy. They explain how it works by stabilizing blood sugar levels, reducing cravings, and leading to significant weight loss over time. The drug, marketed under names like Ozempic and Wegovy, has reportedly caused shortages for diabetes patients due to its newfound fame. They note that while it can help with weight loss, users may regain weight after stopping the drug if they don't change their eating habits. The conversation shifts to the business implications of semaglutide, highlighting the rapid growth of companies like Calibrate, which offers telemedicine services for obtaining prescriptions. The hosts emphasize the potential for content creators to capitalize on the rising interest in these drugs through SEO and affiliate marketing. They also touch on personal experiences with health and fitness, discussing the importance of setting goals and the idea of leveraging one's life for greater fulfillment. The episode concludes with reflections on the nature of success, the importance of choosing the right goals, and the balance between work, fitness, and personal enjoyment. The hosts encourage listeners to take control of their narratives and pursue holistic happiness.

The discussion centers on the use of Ozempic and other GLP-1 agonists for weight loss, highlighting both potential benefits and risks. Experts emphasize the importance of combining these medications with proper nutrition, resistance training, and lifestyle changes to avoid negative impacts on muscle mass and metabolism. Concerns are raised about the long-term health effects of relying solely on these drugs, particularly in children, and the need for a supportive food environment. The conversation critiques the pharmaceutical industry's influence on obesity treatment and stresses that while medications can assist, they should not replace foundational health practices. Ultimately, a holistic approach is deemed essential for sustainable weight management.

The discussion centers around the use of GLP-1 agonist drugs like Ozempic (semaglutide) for weight loss and their implications for long-term health. While these medications can effectively reduce appetite and lead to weight loss, the hosts emphasize that they should not be seen as a magic solution. Sustainable weight loss requires accompanying lifestyle changes, such as improved eating habits and regular exercise. Without these changes, users may face challenges in maintaining their results and could even lose muscle mass. The conversation highlights the importance of addressing the root causes of weight issues rather than merely treating symptoms. The hosts note that while semaglutide is a significant advancement in weight management, it is crucial for users to develop healthy relationships with food and exercise. They caution against relying solely on medication without making behavioral changes, as this could lead to a cycle of dependency on the drug. The popularity of these medications has surged, with celebrities and the general public increasingly seeking them out. The hosts share anecdotes about the growing demand and the challenges faced by individuals trying to access these drugs. They also discuss the potential need for cycling off the medication, similar to other treatments, to avoid long-term dependency. The conversation transitions to the broader implications of lifestyle changes, including the importance of developing a healthy relationship with food and exercise. The hosts stress that individuals must learn to enjoy healthy foods and establish good habits to achieve lasting success. They also touch on the psychological aspects of eating, noting that many people struggle with cravings and emotional eating. In summary, while GLP-1 agonists like Ozempic can aid in weight loss, they are not a standalone solution. Sustainable weight management requires a holistic approach that includes lifestyle changes, exercise, and a focus on building healthy habits. The hosts advocate for coaching and support to help individuals navigate these changes effectively.

The podcast opens by highlighting the dramatic surge in GLP-1 medication use, increasing over 600% since 2021, with projections of two-thirds of the US population eventually using them. The hosts express surprise at the widespread adoption, even among fit individuals, and anticipate further growth with upcoming oral versions. They argue that the prevalence of GLP-1s has revealed a fundamental truth: most people are overweight due to overeating, challenging myths about genetics or metabolism as primary causes. GLP-1s work by inducing powerful satiety, leading to reduced food intake. This, they contend, undermines the "health at every size" movement, as individuals choose medical intervention to lose weight, indicating dissatisfaction with obesity. However, the hosts caution that GLP-1s are not a standalone solution. Weight loss from these drugs often includes significant muscle loss (30-40%), which can slow metabolism and lead to a "skinny fat" physique. They emphasize the critical role of strength training and adequate protein intake to preserve muscle and prevent plateaus. Market trends, like increased protein-focused fast-food options, reflect this need. Drawing from client experiences, the hosts note that many GLP-1 users hit calorie plateaus, requiring strategies like reverse dieting and muscle building. This reinforces the growing importance of personal trainers, who can provide essential guidance on nutrition, exercise, and the challenging process of tapering off GLP-1s to sustain results and avoid weight regain. Beyond weight loss, the discussion shifts to relationship dynamics, referencing a study indicating men's sexual desire peaks in their late 30s/early 40s, correlating with stable, intimate relationships. The hosts suggest that shared goals within a marriage can significantly enhance intimacy, contrasting this with societal emphasis on novelty. They also advocate for incorporating "behind-the-neck" exercises for improved shoulder mobility and posture, especially given increased screen time, and stress the benefits of frequent short breaks from sitting. Listener calls include a successful GLP-1 user who combined the medication with Mind Pump's programs for impressive body recomposition, and a highly muscular female lifter seeking advice on managing rapid strength gains and joint health, leading to recommendations for unilateral and functional training. Another caller, struggling with an "all-or-nothing" approach to fitness and restrictive eating, is advised to seek coaching to reframe her relationship with health and exercise.

Johann Hari discusses his significant weight loss journey, which began after feeling self-conscious at a party where he noticed others had lost weight due to new weight loss drugs like Ozempic. These drugs, including Mounjaro and Triple G, can lead to substantial weight loss and reduce health risks associated with obesity, such as heart attacks and strokes. However, Hari expresses conflicted feelings about their use, recalling the history of diet drugs that often come with severe side effects. He undertook a year-long exploration of these drugs, interviewing supporters and critics, and found that they work differently from previous weight loss medications by mimicking the hormone GLP-1, which signals fullness. While many experience nausea initially, the drugs can lead to reduced food intake and altered cravings. Hari notes that nearly half of Americans express interest in these drugs, reflecting a cultural shift towards pharmaceutical solutions for weight management. He highlights the alarming rise in obesity rates linked to the consumption of processed foods, which undermine natural satiety signals. The drugs may help restore these signals but come with risks, including potential thyroid cancer and muscle mass loss. Hari warns against their misuse among those at healthy weights and emphasizes the need for careful consideration of the risks versus benefits. Ultimately, he concludes that while these drugs could be transformative, they also reflect deeper societal issues regarding food and health. He advocates for systemic changes to address obesity rather than relying solely on medication.

In this episode, Rich Roll speaks with Johann Hari about the weight loss drug Ozempic and its implications for health and society. Johann shares his personal experience with Ozempic, noting that he felt significantly less hungry after starting the medication, which he describes as a potential game changer in the fight against obesity. He emphasizes that obesity is linked to over 200 diseases and complications, making the risks of obesity a critical consideration when weighing the use of such drugs. Johann reflects on the societal pressures surrounding weight loss and the historical context of obesity, noting that the perception of obesity as a moral failing is deeply ingrained in culture. He discusses the mixed emotions he felt upon taking Ozempic, recognizing the benefits while grappling with feelings of guilt and the fear of being perceived as cheating. He argues that the conversation around these drugs should focus on the nuanced benefits and risks rather than falling into binary judgments of right or wrong. The discussion also touches on the broader implications of these drugs, comparing their potential impact to that of the smartphone revolution. Johann highlights the need for a balanced approach, acknowledging that while these drugs can help some individuals, they do not address the underlying environmental factors contributing to obesity. He shares insights from his research, including the importance of understanding the psychological drivers of eating and the potential for these drugs to disrupt established habits. Rich and Johann explore the risks associated with long-term use of weight loss drugs, including the possibility of regaining weight after discontinuation and the psychological effects that may arise. Johann expresses concern about the potential for these drugs to exacerbate eating disorders, particularly among young people who may seek them for aesthetic reasons rather than health. Throughout the conversation, Johann emphasizes the importance of personal responsibility and the need for individuals to engage with their health choices actively. He advocates for a holistic approach that combines the use of medications like Ozempic with lifestyle changes and education about nutrition. The episode concludes with a call for a deeper understanding of the complexities surrounding obesity and the societal structures that contribute to it, urging listeners to consider both the benefits and risks of new weight loss drugs while advocating for systemic change in the food environment.

Jillian Michaels hosts a heated exchange with endocrinologist Karl Nadolsky and Spencer Nadolsky about Ozempic and related GLP-1 therapies for obesity and weight management. The conversation centers on whether obesity should be treated as a disease and how much medical intervention is appropriate versus lifestyle changes, with both sides agreeing that environment and genetics play roles in weight regulation. They scrutinize claims about financial incentives behind these medications and discuss the real-world barriers of access, cost, and adherence, highlighting that patients often struggle to sustain weight loss once medication is stopped. A key portion expands into the efficacy of Wegovy and Ozempic in various populations, including those with and without diabetes, and whether weight loss achieved on these drugs translates into meaningful long-term health benefits. The doctors acknowledge substantial weight reductions in trials but stress that results are influenced by trial design, patient selection, and concomitant lifestyle support. They also concede that some patients experience side effects, with nausea and gallbladder issues cited as notable concerns, while arguing that balanced risk-benefit assessments remain essential for individual care. The guests push back on absolutist claims about medicine versus lifestyle, emphasizing a continuum approach that uses drugs, diet, exercise, and possibly surgical options depending on disease severity. They debate how to define quando to escalate therapy, discuss the potential for weight regain after stopping treatment, and address the broader systemic challenges in obesity care, including insurance coverage and public health policy. The host adds a meta-critique about media misinformation and the need for nuanced, person-centered decisions rather than sensationalized narratives, while signaling future segments to cover topics like muscle loss and other safety signals raised in the wider medical discussion. Topics discussed include the pharmacology and safety signals of GLP-1 drugs, the biology of appetite regulation, the concept of obesity as a disease, the role of lifestyle and environment, cost-effectiveness, and the risk–benefit calculus in real-world treatment, as well as critiques of media portrayal and the influence of industry on research and guidelines. The episode seeks to explore when medications are warranted, how to tailor maintenance strategies, and what patients and clinicians should consider beyond short-term weight loss.

Dr. Tyna Moore discusses the misconceptions surrounding GLP-1 agonists like Ozempic, emphasizing that claims of muscle mass loss and thyroid cancer risk are misleading. She argues that muscle loss associated with these drugs is similar to that seen in any calorically restricted diet and that studies linking GLP-1s to thyroid cancer are correlative, not causative. Moore also addresses concerns about gastroparesis, clarifying that it is not a permanent condition and often pre-exists in patients with type 2 diabetes. Moore, a licensed naturopathic physician, advocates for the potential benefits of GLP-1 agonists beyond weight loss, including improvements in cognitive function, autoimmune conditions, and metabolic health. She emphasizes the importance of using these drugs in low, individualized doses, particularly through compounded versions, which allow for more flexibility in treatment. Her personal journey with these medications began when she experienced cognitive decline and autoimmune flare-ups, leading her to explore their regenerative properties. She critiques the mainstream media's portrayal of GLP-1s and the backlash from the wellness community, noting that many influencers have prematurely condemned these drugs without considering the nuanced benefits they may offer. Moore believes that the conversation around obesity and metabolic health needs to shift from a one-size-fits-all approach to a more personalized strategy, incorporating lifestyle changes alongside medication. Moore highlights the importance of addressing the obesity epidemic through both pharmacological and lifestyle interventions, advocating for comprehensive programs that include nutritional counseling and exercise. She expresses concern about the potential for misuse of GLP-1s, particularly among those seeking rapid weight loss, and stresses the need for proper education and monitoring when using these medications. She also discusses the broader implications of metabolic dysfunction on public health, including its impact on fertility and chronic disease prevalence. Moore calls for a cultural shift in how society approaches health and wellness, emphasizing the need for proactive measures rather than reactive solutions. In conclusion, Moore encourages individuals to educate themselves about GLP-1s and metabolic health, advocating for a balanced approach that combines medication with lifestyle changes. She offers resources through her podcast and courses to help others navigate this complex landscape and improve their overall health.

Dr. Tyna Moore discusses the controversial GLP-1 agonists, highlighting their potential benefits beyond weight loss, particularly in neurocognitive health and inflammation. Initially drawn to the research due to personal health issues and family history of neurodegenerative diseases, she found that mainstream narratives often oversimplify the drugs' effects, focusing primarily on weight loss and type 2 diabetes. Moore emphasizes that GLP-1 receptors are widespread in the body and can have regenerative and anti-inflammatory effects. She argues that the conversation should shift from merely weight loss to the broader health implications, including potential benefits for conditions like Alzheimer's disease. Studies indicate that GLP-1 agonists may reduce neuroinflammation, amyloid plaque aggregation, and neuronal apoptosis, while enhancing neuroplasticity and overall brain health. Moore critiques the high dosing strategies often employed, suggesting that many patients could benefit from lower doses tailored to individual needs. She notes that the side effects reported in the media, such as gastrointestinal issues, may be exaggerated and often stem from aggressive dosing protocols. She advocates for a comprehensive approach to health that includes proper nutrition, exercise, and possibly hormone replacement therapy, alongside the responsible use of GLP-1 agonists. Moore believes that these drugs can serve as a valuable tool in managing obesity and metabolic dysfunction, especially when combined with lifestyle modifications. She stresses the importance of personalized treatment plans and the need for a nuanced understanding of these medications in the context of overall health.